ARS Pharmaceuticals
SPRY
203 hedge funds and large institutions have $758M invested in ARS Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 57 reducing their positions, and 25 closing their positions.
294% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $532K
64% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 25
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
7% more funds holding
Funds holding: 190 → 203 (+13)
3.58% more ownership
Funds ownership: 91.2% → 94.77% (+3.6%)
7% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 57
28% less capital invested
Capital invested by funds: $1.05B → $758M (-$292M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$27M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$17.3M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$9.51M |
| 4 |
TCM
Tyro Capital Management
Miami,
Florida
|
+$9.33M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$18.6M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
-$17.5M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$7.5M |
| 4 |
PCM
Pavaki Capital Management
Pueblo,
Colorado
|
-$5.71M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.88M |
SPRY Hedge Fund Activity: Q1 2026 in Review
203 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2026, worth a combined $758M — down 28% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SPRY positions and 25 closed out — a net gain of 16 holders — while 61 added to existing stakes and 57 trimmed.
The largest buyer was Millennium Management, adding an estimated $27M. The largest seller was Casdin Capital, exiting entirely with an estimated $18.6M sold.
- 203 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2026, up from 190 in Q4 2025.
- Funds reported $758M of ARS Pharmaceuticals stock for Q1 2026, down 28% quarter-over-quarter.
- 41 funds opened new ARS Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +16 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2026 was Millennium Management, an estimated $27M added.
- The largest ARS Pharmaceuticals seller in Q1 2026 was Casdin Capital, an estimated $18.6M sold.
Based on aggregated 13F filings for Q1 2026.